NAMPT: A critical driver and therapeutic target for cancer-Reference-Cited by-同舟云学术

NAMPT: A critical driver and therapeutic target for cancer

Published:2022-04 Issue: Volume:145 Page:106189
ISSN:1357-2725
Container-title:The International Journal of Biochemistry & Cell Biology
language:en
Short-container-title:The International Journal of Biochemistry & Cell Biology

Author:

Gasparrini Massimiliano,Audrito Valentina

Funder

Italian Association for Cancer Research

Publisher

Elsevier BV

Subject

Cell Biology,Biochemistry

Reference107 articles.

1. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis;Adya;Cardiovasc. Res.,2008

2. Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia;Audrito;Blood,2015

3. Nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic target in BRAF-mutated metastatic melanoma;Audrito;J. Natl. Cancer Inst.,2018

4. Targeting metabolic reprogramming in metastatic melanoma: the key role of nicotinamide phosphoribosyltransferase (NAMPT);Audrito;Semin. Cell Dev. Biol.,2019

5. NAD-biosynthetic and consuming enzymes as central players of metabolic regulation of innate and adaptive immune responses in cancer;Audrito;Front. Immunol.,2019

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biological Functions and Therapeutic Potential of NAD+ Metabolism in Gynecological Cancers;Cancers;2024-09-05

2. New Analogues of the Nicotinamide Phosphoribosyltransferase Inhibitor FK866 as Potential Anti-Pancreatic Cancer Agents;Medicinal Chemistry;2024-08

3. Dual-targeted NAMPT inhibitors as a progressive strategy for cancer therapy;Bioorganic Chemistry;2024-08

4. CircABHD2 Inhibits Malignant Progression of Endometrial Cancer by Regulating NAD+/NAMPT Metabolism Axis;Molecular Biotechnology;2024-07-01

5. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) in cancer: a patent review;Expert Opinion on Therapeutic Patents;2024-06-13